- Home
- QXO vs BBIO Comparison
QXO vs BBIO Comparison
Compare QXO & BBIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | QXO | BBIO |
|---|---|---|
| Founded | 1988 | 2015 |
| Country | United States | United States |
| Employees | 7794 | N/A |
| Industry | EDP Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 13.8B | 15.3B |
| IPO Year | N/A | 2019 |
Fundamental Metrics
Financial Performance| Metric | QXO | BBIO |
|---|---|---|
| Price | $24.12 | $76.75 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 13 | 25 |
| Target Price | $32.75 | ★ $86.04 |
| AVG Volume (30 Days) | ★ 7.8M | 1.5M |
| Earning Date | 05-07-2026 | 04-29-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $502,076,000.00 |
| Revenue This Year | $70.82 | $89.45 |
| Revenue Next Year | $38.75 | $73.78 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 126.26 |
| 52 Week Low | $11.97 | $31.77 |
| 52 Week High | $27.61 | $84.94 |
Technical Indicators
Market Signals| Indicator | QXO | BBIO |
|---|---|---|
| Relative Strength Index (RSI) | 62.97 | 58.88 |
| Support Level | $18.48 | $69.62 |
| Resistance Level | $26.24 | $78.20 |
| Average True Range (ATR) | 0.96 | 2.67 |
| MACD | 0.64 | 0.34 |
| Stochastic Oscillator | 81.46 | 67.98 |
Price Performance
Historical ComparisonAbout QXO QXO Inc.
QXO Inc is a publicly traded distributor of building products in North America. The company is executing its plan to become the tech-enabled leader in the around $800 billion building products distribution industry and generate outsized value for its shareholders. The group expects to achieve its target of nearly $50 billion in annual revenues within the next decade through accretive acquisitions and organic growth.
About BBIO BridgeBio Pharma Inc.
BridgeBio Pharma is a biotechnology company focused on discovering, developing, testing, and delivering transformative treatments for patients with genetic diseases. The company has four programs in its late-stage pipeline focusing on Mendelian disorders, oncology, and gene therapy. One of its key programs, Attruby (acoramidis), is an orally administered small molecule designed to stabilize tetrameric transthyretin for the treatment of transthyretin amyloid cardiomyopathy.